Arginine deprivation in cancer therapy

Lynn G Feun, Macus Tien Kuo, Niramol Savaraj

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose of review There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.

Recent findings New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.

Summary Arg deprivation is a promising approach for the treatment of various malignancies.

Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Arginine
Neoplasms
Arginase
Therapeutics
Argininosuccinate Synthase
Cell Death
Down-Regulation
Clinical Trials
Amino Acids
Enzymes
Pharmaceutical Preparations
Genes

Keywords

  • Arg
  • Arg deiminase
  • Arginase
  • Cancer

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Arginine deprivation in cancer therapy. / Feun, Lynn G; Kuo, Macus Tien; Savaraj, Niramol.

In: Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 18, No. 1, 01.01.2014, p. 78-82.

Research output: Contribution to journalArticle

@article{bc44d560c3164bcb86b839eaf09618af,
title = "Arginine deprivation in cancer therapy",
abstract = "Purpose of review There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.Recent findings New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.Summary Arg deprivation is a promising approach for the treatment of various malignancies.",
keywords = "Arg, Arg deiminase, Arginase, Cancer",
author = "Feun, {Lynn G} and Kuo, {Macus Tien} and Niramol Savaraj",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MCO.0000000000000122",
language = "English",
volume = "18",
pages = "78--82",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Arginine deprivation in cancer therapy

AU - Feun, Lynn G

AU - Kuo, Macus Tien

AU - Savaraj, Niramol

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose of review There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.Recent findings New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.Summary Arg deprivation is a promising approach for the treatment of various malignancies.

AB - Purpose of review There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase.Recent findings New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies.Summary Arg deprivation is a promising approach for the treatment of various malignancies.

KW - Arg

KW - Arg deiminase

KW - Arginase

KW - Cancer

UR - http://www.scopus.com/inward/record.url?scp=84916624777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916624777&partnerID=8YFLogxK

U2 - 10.1097/MCO.0000000000000122

DO - 10.1097/MCO.0000000000000122

M3 - Article

C2 - 25474015

AN - SCOPUS:84916624777

VL - 18

SP - 78

EP - 82

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 1

ER -